Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysisPatricia Cortazar, Gϋnter von Minckwitz, Lijun Zhang et al.|The Lancet|2014Cited by 4.7k
Adjuvant Olaparib for Patients with <i>BRCA1</i> - or <i>BRCA2</i> -Mutated Breast CancerAndrew Tutt, Charles E. Geyer|New England Journal of Medicine|2021Cited by 1.6k
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upSibylle Loibl, Nadia Harbeck, Shaheenah Dawood et al.|Annals of Oncology|2023Cited by 830
Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightnessOtto Metzger, Daniel G. Stover, Katharine A. Collier et al.|npj Breast Cancer|2021Cited by 37